Navigation Links
Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
Date:1/28/2008

ANN ARBOR, Mich., Jan. 28 /PRNewswire/ -- Velcura Therapeutics Inc., an early stage biotechnology company developing therapies for bone disease, recently completed a successful Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA). The IND enables Velcura to proceed with the first-in-man clinical trials for its lead compound, VEL-0230.

VEL-0230 is a new chemical entity that has dual-acting properties, in that it both stimulates bone formation and inhibits bone loss. As part of the application, Velcura presented efficacy, safety, and toxicology data to the FDA, as well as plans for its early-stage clinical trials of VEL-0230. The company plans to investigate VEL-0230 as a treatment of diseases involving bone mineral disorders, such as bone loss related to multiple myeloma, bone metastases, rheumatoid arthritis and osteoporosis.

"The successful completion of the FDA's evaluation within the 30-day review period validates our pre-clinical work and allows us to begin studies of VEL-0230 in humans. Its dual-action bone properties make VEL-0203 an ideal therapy for treating multiple bone diseases," said Michael W. Long, Ph.D., President and Chief Executive Officer of Velcura. "We plan to move into multiple clinical studies as rapidly as possible."

VEL-0230 is being studied as an orally available molecule that promotes bone formation, inhibits bone loss and reduces plasma calcium levels. Extensive laboratory investigations, in vivo animal models, and non-clinical toxicology evaluations demonstrate that VEL-0230 is a safe and effective molecule in these systems. The first phase of clinical trials in humans is planned to begin at the end of February 2008.

About Velcura Therapeutics, Inc.

Velcura Therapeutics Inc. is an early stage biotechnology company headquartered in Ann Arbor, Michigan. Velcura's research focus is to understand human bone disease and to discover novel therapeutics that restore bo
'/>"/>

SOURCE Velcura Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
2. Former Pfizer Director of Inflammation Molecular Sciences to Spearhead Velcura Therapeutics Inflammatory Disease Initiatives
3. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
4. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
5. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
6. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
7. Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
8. Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes
9. ARYx Therapeutics, Inc. Announces Pricing of its Initial Public Offering
10. Bioenergy Life Science and Integrative Therapeutics, Inc. Form Exclusive Co-Marketing Alliance
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...y on creativity, sponsored by the Jerusalem-based ...eker, revealed that a majority of the Israeli scie...al methods that could "put them into a creati...s desired." , Jerusa...ey on creativity, sponsored by the Jerusalem-based...
(Date:7/24/2008)...-FirstCall/ -- NuVasive, Inc.,(Nasdaq: NUVA ), a ...cts for,minimally disruptive surgical treatments f...d the previously announced acquisition of the Oste...Inc. (Nasdaq: OSIR ) for $35,million in cash, plu...ot to,exceed $50 million in either cash or stock, ...
(Date:7/24/2008)...nary and critical care clinicians, and resear... DURHAM, N.C., July 24 /- bioMerieux...nferences of the American Thoracic Society and,Soc...sts, pulmonary and,critical care physicians, and r...thods and technologies are needed to quickly diagn...
(Date:7/24/2008)...e/ -- Instrumentation Laboratory,(IL) today announ...ervices,company, has awarded the Company with a fi...ts and services. Broadlane, based in Dallas, TX, c...ospitals, more than 2,600,sub-acute care facilitie...contract covers IL,s portfolio of critical care an...
Breaking Biology Technology:Project Mind Survey of Israeli Ph.D. Scientists Favors a New Standard of Creativity in Science 2Project Mind Survey of Israeli Ph.D. Scientists Favors a New Standard of Creativity in Science 3NuVasive Completes Acquisition of Osteocel Biologics Business 2NuVasive Completes Acquisition of Osteocel Biologics Business 3NuVasive Completes Acquisition of Osteocel Biologics Business 4NuVasive Completes Acquisition of Osteocel Biologics Business 5U.S. Clinicians Indicate a Strong Need for New Tools to Combat Sepsis 2U.S. Clinicians Indicate a Strong Need for New Tools to Combat Sepsis 3Instrumentation Laboratory Announces Contract for Multi-Parameter Testing Products with Broadlane 2
...WR , ECL™ Semi-dry Blotters are desi...er results using low current and voltage with a mi...s available with and without built-in power suppli... Complete, uniform electrotransfer of proteins f... • Minimal buffer use—just enough...
...phopeptide • two-dimensional liquid chromatog...ull; reversed-phase chromatography (RPC) • st...inear ion trap mass spectrometer, , ... phospho-peptides in mouse brain tissue. The tryps...exchange chromatography (SCX), followed by reverse...
...onucleus assays • toxicology • image ana...icronucleus induction is a key characteristic of g...mation resulting from DNA strand breakage (clastog...aneugens) is an important component of toxicology ...f micronucleus assays is time consuming and subjec...
...nalyzer • apoptosis • multiplexing ...tosis represents a gene-directed, morphologically ... death. Inappropriate control of apoptosis is asso...ncer, AIDS, neurodegenerative diseases, and ischae...optosis is extremely important when considering th...
Other Biology Technology:ECL Semi-dry Blotters 22D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 22D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 32D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 42D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 52D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 6Analysis of in vitro micronucleus assays using the IN Cell Analyzer 3000 Micronuclei Formation Analysis Module 2Analysis of in vitro micronucleus assays using the IN Cell Analyzer 3000 Micronuclei Formation Analysis Module 3Analysis of in vitro micronucleus assays using the IN Cell Analyzer 3000 Micronuclei Formation Analysis Module 4Analysis of in vitro micronucleus assays using the IN Cell Analyzer 3000 Micronuclei Formation Analysis Module 5The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays 2The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays 3The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays 4The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays 5The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays 6The measurement of DNA condensation and mitochondrial changes during apoptosis and necrosis in cell based assays 7
(Date:7/24/2008)... study by researchers from Columbia University,s M...e most challenging issues in infant health and pre...ountries. In these settings, HIV-infected mothers...eir infants, they should exclusively breast-feed, ...er birth. But according to the study conducted in ...
(Date:7/24/2008)..., 2008 In the life of a cell, the response to DNA...use and repair itself, commit suicide, or grow unc...tudy, published in the July 25th issue of Cell , ...tified a way that cells respond to DNA damage thro...The finding points to a new pathway for the develo...
(Date:7/24/2008)...UL (July 24, 2008) A multi-institutional team of ...y of Minnesota Medical School, have developed a po... robust method will allow researchers to generate ...NA sequences for inactivation or repair. , The po...h.D., director of the Arnold and Mabel Beckman Cen...
(Date:7/24/2008)..., Iowa The University of Iowa and Iowa State Univ...y enhance both institutions, genetic research capa...ased a massively parallel DNA sequencer an instru...ate of millions to billions of bases in a single r... will be available on a fee-for-service basis to r...
Breaking Biology News(10 mins):Early cessation of breastfeeding by HIV+ women in poor countries and child survival 2Early cessation of breastfeeding by HIV+ women in poor countries and child survival 3A new cellular pathway linked to cancer is identified by NYU researchers 2Consortium develops new method to manipulate genetic material 2UI and ISU establish shared DNA sequencing instrumentation 2UI and ISU establish shared DNA sequencing instrumentation 3Charles S Cohen Pacific Design Center Augment Their Support for AIDS Walk Los Angeles 3951 1Charles S Cohen Pacific Design Center Augment Their Support for AIDS Walk Los Angeles 3951 2Charles S Cohen Pacific Design Center Augment Their Support for AIDS Walk Los Angeles 3951 3TopSpin Medical Appoints Cindy Setum Ph D Vice President Clinical Affairs 1321 1TopSpin Medical Appoints Cindy Setum Ph D Vice President Clinical Affairs 1321 29 Wiley authors win Nobel Prizes 3949 19 Wiley authors win Nobel Prizes 3949 2PainCare Holdings and MedeFile International Form Partnership to Market Personal Electronic Medical Records Direct to Consumers 3947 1PainCare Holdings and MedeFile International Form Partnership to Market Personal Electronic Medical Records Direct to Consumers 3947 2PainCare Holdings and MedeFile International Form Partnership to Market Personal Electronic Medical Records Direct to Consumers 3947 3PainCare Holdings and MedeFile International Form Partnership to Market Personal Electronic Medical Records Direct to Consumers 3947 4PainCare Holdings and MedeFile International Form Partnership to Market Personal Electronic Medical Records Direct to Consumers 3947 5PainCare Holdings and MedeFile International Form Partnership to Market Personal Electronic Medical Records Direct to Consumers 3947 6
...y (NYUCD) research team has found the first oral b...rn Homo sapiens out of Africa to Asia. , The te... and comprehensive care at NYUCD, discovered that ...dental caries, has evolved along with its human ho...ingle common ancestor who lived in Africa between ...
...ve care unit (ICU) already are seriously ill, so t...tunately, statistics show that as many as 25 perce...on ventilators develop pneumonia, which can be fat...ause of infection in the hospital, and studies hav...ts and double the length of stay of the patient in...
...learn skills from each other, in the same manner a...mbridge researcher. , Dr Antonio Moura, a Brazilia...hropology, has discovered signs that Capuchin monk...o ward off potential predators. , While not co...evidence that suggests other species have somethin...
...l fuel air pollution in the United States by analy...nwide. , This novel way to measure carbon dioxid...ll help atmospheric scientists better understand w...es in the air. Tracking fossil-fuel-emitted carbon... the world adhere to the Kyoto Protocol, an agreem...
Other Biology News:'Ancestral eve' was mother of all tooth decay 2Bacteria from patient's dental plaque causes ventilator-associated pneumonia 2New evidence of 'human' culture among primates 2New evidence of 'human' culture among primates 3Scientists map air pollution using corn grown in US fields 2
siTrio siRNA --- a cocktail of 3 siRNAs specifically targeted to your target gene of interestis our most popular product. The siTrio reagent guarantees you get more than 75% knockdown of your target
...eaction module is used for nucleic acid amplificat...erchangeable 96-well reaction module (15-100 micro...ules for real-time PCR and features temperature mo...mple probe. It includes the iCycler base with 96 x...
... stackable multi-function incubator. It uses a mic... to accurately control temperature and agitation s...temperature in the incubator. Temperature can be e...r. Built in maintenance-free stepping motor for hy...
Anti Autotaxin /ENPP2 , - (Rabbit)
Biology Products: